Meta分析二甲双胍对非酒精性脂肪性肝病的疗效.doc

Meta分析：二甲双胍对非酒精性脂肪性肝病的疗效 姚巧玲 刘畅 姜政 重庆医科大学第一附属医院消化内科，重庆，400016 Abstract: Background:The prevalence of non-alcoholic fatty liver disease(NAFLD) is rising, the disease spectrumincluding nonalcoholic fatty liver(NAFL)、non-alcoholic steatohepatitis(NASH) and related cirrhosis and hepatocellular carcinoma。The basic treatments include diet and exercise therapy，but no ideal drugs at this time.Many researchers conducted a series of animal experiments and clinical studies to whether metformin has effect to nafld。 Aim:evaluating the effect of metformin to biochemical outcomes of non-alcoholic fatty liver disease patients。 Methods:By computer search,the data of thirteen randomized controlled clinical trials were searched. Meta-analyses were performed, by Review manager5.0 statistical software with assessment for heterogeneity。 Results:Comparing with diet/exercise therapy/placebo/hepatoprotectants,metformin can improve the level of ALT and AST,the weighted mean differences (WMDs) were -22.72U/L(95%CI:-31.66，p＜0.00001),-10.99U/L(95%CI:-16.04，-5.95，p＜0.0001)。At the sametime,meformin also can improve the level of TC and TG,the weighted mean differences (WMDs) were -0.59mmol/L(95%CI:-1.08，-0.10，p=0.02)，-0.48mmol/L(95%CI:-0.70，-0.26，p＜0.0001)obviously ,the weighted mean difference (WMD) was -0.62（95%CI:-0.，-0.，p=0.00）But through the study data,metformin cannot improve the level of BMI,the weighted mean difference (WMD) was -1.54Kg/㎡(95%CI:-3.22,0.15，p=0.）Conclusion:Metformin can improve the level of ALT、AST、TC、TG and obviously improve the insulin resistance of-alcoholic fatty liver disease patients.the study data suggests that metformin has therapeutic effect to non-alcoholic fatty liver disease patients。 Key words:metformin； non-alcoholic fatty liver disease；treatment；meta-analysis。 摘要： 背景：非酒精性脂肪性肝病（NAFLD）近年来发病率日益上升，其疾病谱包括非酒精性单纯性脂肪肝(NAFL) 、非酒精性脂肪性肝炎(NASH)及其相关肝硬化和肝细胞癌[1] 。饮食及运动治疗是基石，但目前尚无理想的治疗药物。众多研究者就二甲双胍对非酒精性脂肪性肝病是否有疗效进行了一系列的动物实验和临床研究。目的：本研究目的主要是评估二甲双胍对非酒精性脂肪性肝病患者的生化指标的影响。